Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 5, 1999, Pages 402-408

  Weitman, Steven ^a,b   Mangold, Gina ^a   Marty, Jennifer ^a   Dexter, Daniel ^a   Hilsenbeck, Susan ^b   Rake, James ^c   Juniewicz, Paul ^c   Von Hoff, Daniel ^b,c  

^a CTRC Institute for Drug Development   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Sanofi Pharmaceuticals Inc   (United States)

Author keywords

Lung cancer; Platinum; Taxol; Tirapazamine

Indexed keywords

CARBOPLATIN; PACLITAXEL; TIRAPAZAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DNA STRAND BREAKAGE; DRUG EFFICACY; GROWTH INHIBITION; IN VIVO STUDY; LUNG CANCER; LUNG CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR MODEL; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DRUG SYNERGISM; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PACLITAXEL; TRANSPLANTATION, HETEROLOGOUS; TRIAZINES; TUMOR CELLS, CULTURED;

EID: 0032988624     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050914     Document Type: Article

References (34)

1. Barry MA, Behnke CA, Eastman A (1990) Activation of programmed cell death (apoptosis) by cisplatin, other anticancer-drugs, toxins and hyperthermia. Biochem Pharmacol 40: 2353
2. Box GEP, Cox DR (1964) Analysis of transformations. J R Statist Soc 26: 211
3. Choy H, Akerley W, Safran H, Graziano S, Chung C (1996) Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced non-small-cell lung cancer. Semin Oncol 23 [Suppl. 16]: 117
4. Clark SJ, Boyer M (1997) Recent advances in managing non-small-cell lung cancer: chemotherapy of metastatic cancer. Med J Aust 166 [Suppl. 2]: S14
5. Current Clinical Trials-Oncology (1997) 4: I-183
6. Delahoussaye YM, Wouters BG, Evans JE, Brown JM (1997) Intranuclear metabolism of tirapazamine by matrix-associated reductases. Proc Am Assoc Cancer Res 38: 163
7. Dorie MJ, Brown JM (1993) Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 53: 4633
8. Dorie MJ, Brown JM (1997) Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic-agent tirapazamine. Cancer Chemother Pharmacol 39: 361
9. Edelman MJ, Gandara DR (1996) Promising new agents in the treatment of non-small cell lung cancer. Cancer Chemother Pharmacol 37: 385
10. Evans JW, Brown JM (1997) The hypoxic toxicity of tirapazamine results from intranuclear reduction of the drug. Proc Am Assoc Cancer Res 38: 246
11. Fitzsimmons SA, Lewis AD, Riley RJ, Workman P (1994) Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase. Carcinogenesis 15: 1503
12. Graham MA, Senan S, Rampling R, Robin H, Eckardt N, Lendrem D, Hincks J, Greenslade D, Rampling R, Kaye SB, Roemeling R von, Workman P (1997) Pharmacokinetics of the-hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Cancer Chemother Pharmacol 40: 1
13. Hanauske AR, Ross M, Degen D, Hilsenbeck SG, Von Hoff DD (1993) In vitro activity of the benzotriazene dioxide SR-4233 against human tumour colony-forming units. Eur J Cancer 29A: 423
14. Herman TS, Teicher BA, Coleman CN (1990) Interaction of SR4233 with hyperthermia and radiation in the FSaIIc murine fibrosarcoma tumor system in vitro and in vivo. Cancer Res 50: 7745
15. Hochberg Y, Tamhane AC (1987) Multiple comparison procedures. John Wiley and Sons, New York
16. Holden SA, Teicher BA, Ara G, Herman TS, Coleman CN (1992) Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma. J Natl Cancer Inst 84: 187
17. Johnson CA, Kilpatrick D, Roemeling R von, Langer C, Graham MA, Greenslade D, Kennedy G, Keenan E, O'Dwyer PJ (1997) Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors. J Clin Oncol 15: 773
18. Kelner MJ, McMorris TC, Estes L, Starr R, Samson K, Varki N, Taetle R (1995) Nonresponsiveness of the metastatic human-lung carcinoma MV522 xenograft to conventional anticancer agents. Anticancer Res 15: 867
19. 131I-labeled antibody and the hypoxic cytotoxin SR 4233 in vitro and in vivo. Radiat Res 132: 351
20. Langmuir VK, Rooker JA, Osen M, Mendonca HL, Laderoute KR (1994) Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts. Cancer-Res 54: 2845
21. Lartigau E, Guichard M (1996) The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours. Br J Cancer 73: 1480
22. Lin PS, Ho KC, Yang SJ (1996) Tirapazamine (SR 4233) interrupts cell cycle progression and induces apoptosis. Cancer Lett 105: 249
23. Natale RB (1997) Overview of current and future chemotherapeutic agents in non-small-cell lung cancer. Semin Oncol 24 [Suppl. 7]: S29
24. Patterson AV, Barham HM, Chinje EC, Adams GE, Harris AL, Stratford IJ (1995) Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br J Cancer 72: 1144
25. Riley RJ, Hemingway SA, Graham MA, Workman P (1993) Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233). Biochem Pharmacol 45: 1065
26. Rodriguez GI, Valdivesco M, Von Hoff DD, Kradt M, Burris HA, Eckardt JR, Fields SM, Smith B, Graham M, Greenslade D, Roemeling R von (1995) Phase I trial of tirapazamine (Tira; SR 4233; WIN 59075) and cisplatin for advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14: 475
27. Senan S, Rampling R, Graham MA, Wilson P, Robin H, Eckardt N, Lawson N, McDonald A, Roemeling R von, Workman P, Kaye SB (1997) Phase I and pharmacokinetic-study of tirapazamine (SR 4233) administered every three weeks. Clin Cancer Res 3: 31
28. Siim BG, Menke DR, Dorie MJ, Brown JM (1997) Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Cancer Res 57: 2922
29. Sun JR, Brown JM (1989) Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR 4233 in a murine carcinoma. Cancer Res 49: 5664
30. Vokes EE, Leopold KA, Herndon J, Green MR (1997) Investigations of new drugs in combination with cisplatin in stage III non-small-cell lung cancer. Semin Oncol 24 [Suppl. 8]: S42
31. Wouters BG, Giaccia AJ, Delahoussaye YM, Brown JM (1997) Tirapazamine induces apoptosis by p53-dependent and p53-independent mechanisms. Proc Am Assoc Cancer Res 38: 246
32. Zeman EM, Brown JM (1989) Pre- and post-irradiation radiosensitization by SR4233. Int J Radiat Oncol Biol Phys 16: 967
33. Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW (1986) SR4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12: 1239
34. Zeman EM, Lemmon MJ, Brown JM (1990) Aerobic radiosensitization by SR4233 in vitro and in vivo. Int J Radiat Oncol Biol Phys 18: 125